Docket No.: 16534-539001US Applicants: Levy, et al.

Serial No.: 10/692,764

Filing Date: October 24, 2003

Page -3-

## AMENDMENTS TO THE CLAIMS:

## **Listing of Claims:**

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1. (Currently Amended) A method for treating a subject for a DTMR associated with splicing of nuclear RNA, comprising: administering to said subject an effective amount of a tetracycline compound of formula (I):

wherein

R<sup>2</sup>. R<sup>2</sup>', R<sup>4</sup>', and R<sup>4</sup>'' are each independently hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R<sup>3</sup>. R<sup>10</sup>, R<sup>11</sup> and R<sup>12</sup> are each hydrogen, alkyl, alkenyl, alkynyl, substituted carbonyl, or a pro-drug moiety;

R<sup>4</sup> is NR<sup>4</sup> R<sup>4</sup>, alkyl, alkenyl, alkynyl, hydroxyl, halogen, or hydrogen;

R<sup>5</sup> is hydroxyl, hydrogen, thiol, alkanoyl, aroyl, alkaroyl, aryl, heteroaromatic. alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, alkyl carbonyloxy, or aryl carbonyloxy;

R<sup>6</sup> and R<sup>6</sup> are each independently hydrogen, methylene, absent, hydroxyl, halogen, thiol, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

R<sup>7</sup> is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or –(CH<sub>2</sub>)<sub>0-3</sub>NR<sup>7c</sup>C(=W')WR<sup>7a</sup>;

Applicants: Levy, et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -4-

 $R^8$  is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or  $-(CH_2)_{0-3}NR^{8c}C(=E')ER^{8a}$ ;

 $R^9$  is hydrogen, hydroxyl, halogen, thiol, nitro, alkyl, alkenyl, alkynyl, aryl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, arylalkyl, amino, arylalkenyl, arylalkynyl, acyl, aminoalkyl, heterocyclic, thionitroso, or  $-(CH_2)_{0-3}NR^{9c}C(=Z')ZR^{9a}$ ;

R<sup>7a</sup>, R<sup>7b</sup>, R<sup>7c</sup>, R<sup>7d</sup>, R<sup>7e</sup>, R<sup>7f</sup>, R<sup>8a</sup>, R<sup>8b</sup>, R<sup>8c</sup>, R<sup>8d</sup>, R<sup>8e</sup>, R<sup>8f</sup>, R<sup>9a</sup>, R<sup>9b</sup>, R<sup>9c</sup>, R<sup>9d</sup>, R<sup>9e</sup>, and R<sup>8f</sup> are each independently hydrogen, acyl, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, arylalkyl, aryl, heterocyclic, heteroaromatic or a prodrug moiety;

R<sup>13</sup> is hydrogen, hydroxy, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, aryl, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

E is CR<sup>8d</sup>R<sup>8e</sup>, S, NR<sup>8b</sup> or O;

E' is O, NR<sup>8f</sup>, or S;

W is CR<sup>7d</sup>R<sup>7e</sup>, S, NR<sup>7b</sup> or O;

W' is O, NR<sup>7f</sup>, or S;

X is CHC(R<sup>13</sup>Y'Y), C=CR<sup>13</sup>Y, CR<sup>6</sup>'R<sup>6</sup>, S, NR<sup>6</sup>, or O;

Y' and Y are each independently hydrogen, halogen, hydroxyl, cyano, sulfhydryl, amino, alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylamino, or an arylalkyl;

Z is CR<sup>9d</sup>R<sup>9e</sup>, S, NR<sup>9b</sup> or O; and

Z' is O, S, or NR<sup>9f</sup>, and or a pharmaceutically acceptable salts salt, esters ester and or enantiomers enantiomer thereof, with the proviso that said tetracycline compound is not tetracycline;

such that said DTMR associated with splicing of nuclear RNA is treated, wherein said DTMR associated with splicing of nuclear RNA is spinal muscular atrophy, and further wherein said effective amount is effective to modulate splicing of said subject's nuclear RNA.

Applicants: Levy, et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -5-

## 2.-36. (Canceled)

- 37. (Previously Presented) The method of claim 1, wherein  $R^2$ ,  $R^2$ ,  $R^8$ ,  $R^{10}$ ,  $R^{11}$ , and  $R^{12}$  are each hydrogen, X is  $CR^6R^{6'}$ , and  $R^4$  is  $NR^{4'}R^{4''}$ , wherein  $R^{4'}$  and  $R^{4''}$  are each methyl.
  - 38. (**Original**) The method of claim 37, wherein R<sup>9</sup> is hydrogen.
- 39. (Original) The method of claim 38, wherein  $R^7$  is substituted or unsubstituted aryl.
- 40. (Original) The method of claim 39, wherein  $R^7$  is substituted or unsubstituted phenyl.
- 41. (Original) The method of claim 40, wherein  $R^7$  is substituted with one or more substituents.
- 42. **(Original)** The method of claim 41, wherein said substituents are each independently alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino, acylamino, amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulfinyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, aryl or heterocyclic moiety.

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764

Filing Date: October 24, 2003

Page -6-

- 43. (Original) The method of claim 38, wherein  $R^7$  is substituted or unsubstituted alkenyl.
- 44. (Original) The method of claim 37, wherein  $R^7$  is substituted or unsubstituted heteroaryl and  $R^9$  is alkyl.
  - 45. (Original) The method of claim 36, wherein  $R^7$  is dialkylamino.
  - 46. (Original) The method of claim 45, wherein R<sup>9</sup> is alkylamino.
- 47. **(Original)** The method of claim 45, wherein  $R^9$  is  $-NR^{9c}C(=Z^*)ZR^{9a}$ , wherein  $R^{9c}$  is hydrogen,  $Z^*$  is nitrogen or oxygen, Z is NH, and  $R^{9a}$  is aryl or aralkyl.

## 48.-53. (Canceled)

54. (Currently Amended) The method of claim 1, A method for treating a subject for a DTMR associated with splicing of nuclear RNA, comprising: administering to said subject an effective amount of a tetracycline compound; wherein said tetracycline compound is a tetracycline compound selected from the group consisting of:

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -7-

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -8-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -9-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -10-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -11-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -12-

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -13-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -14-

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -15-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -16-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -17-Docket No.: <u>16534-539001US</u>

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -18-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -20-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -21-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -22-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -23-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -24-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -25-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -26-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -27-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -28-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -29-

pplicants: Levy, et al. Docket No.: 16534-539001US

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -30-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -31-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -32-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -33-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -34-Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -35-

Docket No.: 16534-539001US

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -36-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -37-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -38-Docket No.: <u>16534-539001US</u>

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -39-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -40-Docket No.: <u>16534-539001US</u>

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -41-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -42-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -43-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -44-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -45-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -46-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -47-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -48-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -49-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -50-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -51-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -52-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -53-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -54-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -55-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -56-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -57-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -58-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -59-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -60-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -61-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -62-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -63-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -64-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -65-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -66-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -67-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -68-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -69-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -70-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -71-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -72-

THO HO

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -73-

Applicants: Levy, et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -74-

Applicants: Levy, et al. Serial No.: 10/692,764

Filing Date: October 24, 2003

Page -75-

$$\begin{array}{c|c} CH_3 & \underline{H} & \underline{N} \\ \hline \\ OH & O & OH & O \\ \end{array} \\ \begin{array}{c|c} OH \\ \hline \\ OH & O \\ \end{array}$$

$$\begin{array}{c|c} N & H & \underline{N} & OH \\ \hline OH & O & OH & O \\ \hline OH & O & O & O \\ \end{array}$$

Levy, et al. Docket No.: 16534-539001US

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -76-

$$\begin{array}{c|c} CH_2 & \underline{H} & \underline{N} \\ \hline \\ OH & O & OH & O \\ \end{array} \\ \begin{array}{c|c} OH & \\ \hline \\ OH & O \\ \end{array} \\ \begin{array}{c|c} OH & \\ \hline \\ OH & O \\ \end{array}$$

$$\begin{array}{c|c} CI & \underline{H} & \underline{N} \\ \hline \\ OH & O & OH & O \\ \end{array}$$

$$\begin{array}{c|c} & \underline{H} & \underline{N} \\ \hline \\ \underline{H} & \underline{H} & \underline{N} \\ \hline \\ \underline{OH} & \underline{OH} & \underline{OH} \\ \\ OH & \underline{OH} & \underline{OH} & \underline{OH} \\ \end{array}$$

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -77-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -78-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -79-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -80-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -81-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003 Page -82-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -83-

 $H_3C_N$ C $H_3$ H<sub>3</sub>C<sub>N</sub>CH<sub>3</sub> H<sub>3</sub>C N CH<sub>3</sub> CH3H OH N Н Ю. OH O Ŋ J OHO ÓН <u>H</u> H HO.

Applicants: Levy, et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -84-

$$\begin{array}{c|c} & & & \\ &$$

$$0 \\ \downarrow \\ OH \\ OOH \\ OOH$$

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -85-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -86-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -87-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -88-

ÒН

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -89-

ÓН

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -90-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -91-

$$\begin{array}{c|c} F & H & H & OH \\ \hline & N & OH & OH & OH \\ \hline & OH & O & OH & O \\ \hline \end{array}$$

$$\begin{array}{c|c} & & & \\ &$$

$$\begin{array}{c|c} & & & \\ &$$

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -92-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -93-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -94-

$$\begin{array}{c|c} O & & \\ \hline & H & \underline{N} \\ \hline OH & O & O \\ \hline OH & O & O \\ \end{array}$$

ОН

HO.

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -95-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -96-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -97-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -98-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -99-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -100-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -101-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -102-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -103-

Applicants: Levy, *et al.* Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -104-

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -105-

Applicants: Levy. et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -106-

and pharmaceutically acceptable salts, esters and enantiomers thereof; such that said DTMR associated with splicing of nuclear RNA is treated, wherein said DTMR associated with splicing of nuclear RNA is spinal muscular atrophy, and further wherein said effective amount is effective to modulate splicing of said subject's nuclear RNA.

Applicants: Levy, et al. Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -107-

- 55. (Canceled)
- 56. (Canceled)
- 57. (Currently Amended) The method of claim 1, wherein said tetracycline compound is:

, andor a pharmaceutically acceptable saltssalt thereof.

- 58. (Canceled)
- 59. **(Previously Presented)** The method of claim 1, wherein said modulation of splicing increases splicing of RNA.
- 60. (Previously Presented) The method of claim 1, wherein said modulation of splicing decreases splicing of RNA.
  - 61. (Canceled)
- 62. **(Previously Presented)** The method of claim 1, wherein said subject is a mammal.
- 63. (Previously Presented) The method of claim 62, wherein said mammal is a human.

Applicants: Levy. et al. Docket No.: 16534-539001US

Serial No.: 10/692,764 Filing Date: October 24, 2003

Page -108-

64. **(Previously Presented)** The method of claim 1, wherein said modulation of splicing is activation of cryptic splice sites, silencing of consensus splice sites, silencing of exonic or intronic splicing enhancers (ESEs or ISEs), silencing of exonic or inronic splicing silencers (ESSs or ISSs), alteration of the binding or a component of the splicing machinery to the RNA, or the affecting of intermolecular interactions between components of the splicing machinery.

65. (Currently Amended) The method of claim 1, wherein said tetracycline compound is:

, and or a pharmaceutically acceptable salts salt

thereof.